Title : Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.

Pub. Date : 2014

PMID : 25501110






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 A lower level of BCR-ABL transcript at 1 or 3 months after the initiation of dasatinib treatment was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months (p < 0.001) than a higher level of BCR-ABL. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 A lower level of BCR-ABL transcript at 1 or 3 months after the initiation of dasatinib treatment was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months (p < 0.001) than a higher level of BCR-ABL. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
4 A lower level of BCR-ABL transcript at 1 or 3 months after the initiation of dasatinib treatment was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months (p < 0.001) than a higher level of BCR-ABL. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens